Astec Lifesciences Limited stands as a prominent player in India's agrochemical industry, specializing in the manufacturing of active ingredients, intermediates, and formulations for both domestic and global markets. The Company is engaged in the manufacturing of agrochemical active ingredients (technical), bulk, formulations and intermediate products. Astec LifeSciences is headquartered in Mumbai, India and was originally incorporated as Urshila Traders Pvt Ltd in 1994, before becoming Astec Lifesciences Limited.
The company operates primarily through its agrochemicals segment, offering a comprehensive portfolio of crop protection solutions. The company offers a range of products and intermediates, including fungicides, insecticides, herbicides, and various chemical compounds, serving global customers and including triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, fluorinated compounds, halides, intermediates, ketones, ethers, alcohols, and many others.
Astec Lifesciences has developed significant capabilities in contract development and manufacturing services, particularly focusing on agrochemical solutions. The Company has also developed capabilities and infrastructure which enables it to undertake contract development and manufacturing services for a diverse range of agrochemicals, catering to the needs of global innovators in the sector. Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US.
The company's manufacturing operations are strategically located across Maharashtra, India. They are having manufacturing facilities located at two locations in Maharashtra, India comprising of three units viz. one unit at Dombivli, Maharashtra and two units at Mahad, Maharashtra (Unit 1 and Unit 2). These facilities enable the company to manufacture a wide range of agrochemical active ingredients and pharmaceutical intermediates with consistent quality standards.
Astec Lifesciences has established a strong international presence, exporting its products to multiple countries across different continents. It exports to approximately 17 countries including the United States and countries across Europe, West Asia, South-East Asia and Latin America and Africa. The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries. The company operates exclusively in the business-to-business (B2B) segment, serving crop protection formulators and API manufacturers globally.
As of March 31, 2025, Astec Lifesciences reported mixed financial results. Sales declined 22.26% to Rs 119.53 crore in the quarter ended March 2025 as against Rs 153.75 crore during the previous quarter ended March 2024. Net Loss of Astec Lifesciences reported to Rs 16.09 crore in the quarter ended March 2025 as against net loss of Rs 0.97 crore during the previous quarter ended March 2024.
For the full financial year 2025, the company faced significant challenges. For the full year, net loss reported to Rs 134.75 crore in the year ended March 2025 as against net loss of Rs 46.93 crore during the previous year ended March 2024. Sales declined 16.78% to Rs 381.30 crore in the year ended March 2025 as against Rs 458.18 crore during the previous year ended March 2024.
- Q4 FY25 Performance: Sales of Rs 119.53 crore, Net Loss of Rs 16.09 crore
- FY25 Performance: Sales of Rs 381.30 crore, Net Loss of Rs 134.75 crore
- Operating Margin (Q4 FY25): 4.62% (vs 8.27% in Q4 FY24)
- EBITDA (Q4 FY25): Rs 6.32 crore (down 57.18% from Rs 14.76 crore in Q4 FY24)
- Market Capitalization: Rs 1,820 crore (as of recent trading sessions)
- 52-Week High Share Price: Rs 1,487.65
- 52-Week Low Share Price: Rs 635.95
- Promoter Holding: 70.87% (as of March 2025)
The company maintains a concentrated ownership structure with Promoter holding in Astec Lifesciences Ltd has gone up to 70.87 per cent as of Mar 2025 from 66.75 per cent as of Jun 2024. This indicates continued promoter confidence in the company's long-term prospects. Astec LifeSciences has 446 total employees and operates under the leadership of Chairman N. B. Godrej.
The company has recently announced plans for fundraising to support its growth initiatives. Astec Lifesciences' Board approved a rights issue to raise up to ₹250 crore. Astec LifeSciences shares rose 6% after announcing a board meeting on June 24, 2025, to consider fundraising options. Despite current challenges, the company is focusing on sequential improvements in performance and better product mix optimization.
The company continues to invest in research and development capabilities while maintaining its focus on sustainability and environmental responsibility. Astec LifeSciences publishes FY 2024-25 Business Responsibility & Sustainability Report detailing ESG initiatives and compliance.
With its established manufacturing capabilities, global market presence, and focus on innovation in agrochemical solutions, Astec Lifesciences remains positioned to capitalize on the growing demand for crop protection products in both domestic and international markets, though near-term performance will depend on market recovery and successful execution of its strategic initiatives.
